297 results about "Pulmonary fibroses" patented technology

This invention concerns the method of extracting salvianolic acid A from Chinese crude drug: danshen root, and the quality control methods and drug combinations, and the application of this drug. It can be used in the preparation of the prevention drugs for cardiovascular disease, liver damage, liver fibrosis, pulmonary fibrosis and other.

The present invention provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF; and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-γ to an individual with IPF.

The present invention relates to a compound represented by formula (I-0):wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous disease (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephrtitis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

The present invention relates to a compound represented by formula (I-0): wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

The present application provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF, and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-γ to an individual with IPF.

A compound represented by general formula (I):a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac / vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and / or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

The invention provides a traditional Chinese medicine composition for treating idiopathic pulmonary fibrosis and a preparation method thereof. The traditional Chinese medicine composition comprises, by weight, 13-23 parts of red sage root, 7-17 parts of bulb of fritillary, 4-14 parts of peach seed, 4-14 parts of ligusticum wallichii, 1-11 parts of lumbricus, 7-17 parts of balloonflower root, 13-23 parts of milkvetch root, 7-17 parts of pilose asiabell root, 4-14 parts of fructus psoraleae, 7-17 parts of tuber of dwarf lilyturf and 4-14 parts of Chinese magnoliavine fruit. The traditional Chinese medicine composition effectively treats idiopathic pulmonary fibrosis, is safe and stable, obviously improves human body immunity, especially improve respiratory system immunity, has effects of promoting blood circulation to remove blood stasis, reducing phlegm and dredging collaterals, and tonifying lung, spleen and kidney, relieves disease pain and prolongs a human life.

Compositions, kits and methods for assessing the prognosis of idiopathic pulmonary fibrosis in patients are provided. In addition, compositions, kits and methods for diagnosing subtypes of idiopathic pulmonary fibrosis are provided. Also provided are methods for treating idiopathic pulmonary fibrosis.

The invention relates to compounds of formula (A) and formula (I):or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention discloses a Chinese medicinal composition for treating pulmonary fibrosis and its application. The Chinese medicinal composition consists of the following components by weight: 3.6-4 parts of Bletilla striata, 0.9-1.2 parts of Galla Chinensis, 1-1.2 parts of Bombyx Batryticatus, 4-4.5 parts of rhizoma atractylodis macrocephalae, 4-5 parts of Adenophora elata, 4-4.5 parts of Radix Stemonae, 1-1.2 parts of platycodon grandiflorum, and 7-8 parts of codonopsis pilosula. Research shows that the aqueous extract of the Chinese medicinal composition provided in the invention has an obvious inhibiting effect on a pulmonary fibrosis animal model TGF beta, and the composition can be used for preparing anti-pulmonary fibrosis drugs. In the invention, new application and treatment mechanism of the Chinese medicinal composition are developed. The Chinese medicinal composition is in favor of studying the pulmonary fibrosis mechanism and treatment drugs, and provides an experimental foundation for new drugs treating pulmonary fibrosis.

The invention belongs to the technical field of medicines, and particularly relates to a JNK (stress-activated kinases,SAPK) inhibitor compound as shown in the general formula (I), pharmaceutically acceptable salts or stereoisomers thereof, preparation method of the compounds, pharmaceutical preparations containing the compounds, and use of the compounds in preparing medicines for treatment and / or prevention of ischemia reperfusion injury, diabetes, neurodegenerative diseases, chronic inflammation, pulmonary fibrosis, liver fibrosis, fatty liver and liver cirrhosis, wherein R1, R2, R3, R4 and R5 are as defined in the specification.

The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention relates to the technical field of medicines, and particularly relates to cryptotanshinone for preventing and treating pulmonary fibrosis and an application thereof. The cryptotanshinone (I) is quinone diterpene extracted from the root part of salviae miltiorrhizae; the modern pharmacological research shows that the cryptotanshinone has a bacteriostatic effect, an anti-inflammatory effect and a hormone-like pharmacologic effect, and is clinically used for treating myocardial fibrosis, lung acute injury and arthritis, can be used for preventing and / or treating a pulmonary fibrosis disease, can also be used for preparing medicines for reducing body weight of a pulmonary fibrosis rat, a lung coefficient and the content of hydroxyproline in tissue and can be used for preparing the medicines for reducing the content of IL-1beta, IL-6 and TNF-alpha in a bronchoalveolar lavage liquid and the medicines of effecting the pathogeny structure of pulmonary fibrosis tissue of the rat. The formula (I) is as shown in the specification.

The invention discloses an application of eucheuma polypeptide in the preparation of drugs or health products for the prevention and treatment of pulmonary fibrosis. The eucheuma polypeptide can be used to prepare drugs or health products for the prevention and treatment of pulmonary fibrosis; can be used to modify the precursor of drugs for the prevention and treatment of pulmonary fibrosis; and can be co-used with drugs for treating pulmonary fibrosis to treat pulmonary fibrosis. The eucheuma polypeptide is obtained by extracting and purifying eucheuma, can prominently inhibit the formation of pulmonary fibrosis, has a good effect on preventing and treating pulmonary fibrosis, and has an important application value in the prevention and treatment of pulmonary fibrosis.

The invention belongs to the field of traditional Chinese medicine extraction, and especially relates to a preparation method of high purity cistanche phenyl ethanol glycosides and an application of high purity cistanche phenyl ethanol glycosides in the preparation of drugs for treating pulmonary fibrosis. The preparation method extracts two high purity cistanche phenyl ethanol glycosides from cistanche. The invention specifically discloses a preparation method and applications of high purity cistanche phenyl ethanol glycosides. Three resin columns are used together; Amberlite XAD16HP macroporous resin is used to remove impurities such as sugar; Amberlite FPC22Na (macroporous strongly acidic styrene resin) and D201 (strong alkali I type anion exchange resin) are used to effectively removepigments and components that are not phenyl ethanol glycosides; three resins are screened from a plurality of resins, the extracted cistanche phenyl ethanol glycosides have a light yellow color; the content of total phenyl ethanol glycosides is more than 95% (weight ratio), the content of echinacoside and verbascoside is more than 85% (weight ratio), and the phenyl ethanol extract has a good effect on preventing pulmonary fibrosis.

A compound represented by general formula (I):a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and / or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

Some embodiments of the invention include methods for treating an animal for fibrosis comprising one or more administrations of one or more compositions comprising one or more opioid receptor inhibitors. Other embodiments of the invention further include other fibrosis treatments. Still other embodiments of the invention include methods for treating a human for idiopathic pulmonary fibrosis, comprising administering one or more compositions comprising naltrexone and optionally administering one or more compositions comprising pirfenidone, nintedanib, or both. Additional embodiments of the invention are also discussed herein.

The present invention provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF; and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-γ to an individual with IPF.

The invention relates to the field of medicine synthesis, and discloses a GIP / GLP-1 analogue. The GIP / GLP-1 analogue is used for preparing a pharmaceutical composition for treating diseases, and the pharmaceutical composition is used for preparing a medicine for treating at least one of the following diseases: type-II diabetes, impaired glucose tolerance, type-I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive disorder, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory intestinal syndrome and / or dyspepsia orgastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

<heading lvl="1">SUMMARY OF THE INVENTION < / heading> The use of gene therapy for the treatment of different kinds of fibrosis in human beings is disclosed. The purpose is the use of "therapeutic2 genes specifically directed to target organs to revert and / or prevent the development of the fibrosis process. The potential application of gene therapy to patients with fibrosis and / or cirrhosis will depend to a large extent on the successful delivery of genes which encode for therapeutic proteins to livers with severe fibrosis and that these genes which encode for proteins human MMP-8 active and latent, MMP-1, MMP-2, MMP-9 and MMP-13; human uPA wild type and / or modified (or its truncated version), the truncated receptor for TGF-beta type II and Smad-7 can be directed by adenovirus and / or other recombinant vectors that cannot transduce (infect) others organs. The recombinant adenoviruses (AdR) are vectors highly efficient for the transduction of therapeutic genes to diverse target cells. We have proved that they can carry genes to cirrhotic livers. The delivery of therapeutic genes through such adenoviral vectors and other recombinant vectors could also be performed using cationic and anionic liposomes (DOTMA). Therefore, we propose the use of this patent to be applied in the same manner to: Renal fibrosis Pulmonary fibrosis Hypertrophic and keloid scars (skin fibrosis), and Other kinds of fibrosis.

The invention relates to compounds of formula (A):or a salt thereof, wherein R1, R2, R5a, R5b, R6a, R6b, R7a, R7b, R8a, R8b, R9a, R9b, R10a, R10b, R11a, R11b, R21, n, and G are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αVβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention discloses an ethanesulfonic acid nintedanib dispersible tablet used for treating idiopathic pulmonary fibrosis (IPF). Ethanesulfonic acid nintedanib serves as the raw material, auxiliary materials are added, and the ethanesulfonic acid nintedanib dispersible tablet is prepared. The ethanesulfonic acid nintedanib dispersible tablet is rapid to disintegrate and absorb, high in bioavailability, convenient to take, less in intestinal tract residue, few in side effect and sweet in taste and has fragrance, medicine taking compliance of patients is particularly easy to improve, the taste of the preparation is improved, the sticking phenomenon cannot occur in the tabletting process, and industrial production is promoted.

The invention provides application of pazopanib hydrochloride to preparing medicines for treating pulmonary fibrosis diseases, and further provides a medicine composition. The medicine composition contains the pazopanib hydrochloride, excipients and pharmaceutically acceptable salt, ester and hydrates of the pazopanib hydrochloride or compositions of the salt, the ester and the hydrates. The application and the medicine composition have the advantages that excellent effects can be realized by the pazopanib hydrochloride for pulmonary fibrosis, adverse reaction can be prevented, bleomycin-induced pulmonary fibrosis in mice can be relieved, and the medicine composition has an excellent application prospect for treating, relieving and improving the pulmonary fibrosis diseases.

The invention provides a pulmonary fibrosis detection and severity evaluation method based on deep learning, and the method comprises the steps: S1, preprocessing chest CT sequence images of a plurality of pulmonary fibrosis patients, and obtaining a plurality of first CT images; S2, extracting and labeling a plurality of first CT images to generate a training set and a verification set; S3, pre-training a first deep convolutional neural network model and a second deep convolutional neural network model through the training set and the verification set; S4, inputting the CT image sequence of the patient to be detected into the trained first and second deep convolutional neural network models, and identifying a lung region and a pulmonary fibrosis focus region contained in each CT image inthe CT image sequence of the patient; calculating to obtain the proportion of the pulmonary fibrosis focus of the patient in the lung; S5, marking pulmonary fibrosis staging based on the proportion; and S6, grading the pulmonary fibrosis severity of the patient based on the detection result of the physiological parameters. The invention further comprises a pulmonary fibrosis detection and severityevaluation system based on deep learning.

Disclosed are biomarkers, methods and assay systems for the identification of poor prognosis of interstitial pneumonia (pulmonary fibrosis) in an individual diagnosed with suspected of having interstitial pneumonia.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine combination for treating idiopathic pulmonary fibrosis, and a preparation method and application thereof. According to the invention, Chinese medicinal herbs mutually cooperate and jointly act according to a compatibility relationship of ''monarch, minister, assistant and conductant'' so as to act on a focus to exert an effect of treating idiopathic pulmonary fibrosis. Clinical experiments show that the traditional Chinese medicine combination has a good treatment effect on idiopathic pulmonary fibrosis at acute, sub-acute, chronic and chronic acute onset stages; the total effective rate for idiopathic pulmonary fibrosis is 86.6%; idiopathic pulmonary fibrosis is less prone to recurrence after being cured; and the traditional Chinese medicine combination is free of toxic and side effect and has a wide application value.